Jefferies analyst Maury Raycroft assumed coverage of Inozyme with a Buy rating and price target of $17, up from $16. The company has a “pipeline in a product” with its lead asset INZ-701 with three shots on goal in the clinic, the analyst tells investors in a research note. The firm thinks the ABCC6 deficiency and cacliphylaxis trail sare underappreciated with $2B opportunity that could be de-risked by catalysts in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
- Inozyme reports Q2 EPS (44c), consensus (39c)
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
- Inozyme announces publication of preclinical data on INZ-701
- Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency